Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism

Hiroyuki Hanada, Satomi Mugii, Manabu Okubo, Ikuhiro Maeda, Kazuya Kuwayama, Yoh Hidaka, Rika Kitazume-Taneike, Taiji Yamashita, Ryota Kawase, Hajime Nakaoka, Miwako Inagaki, Miyako Yuasa-Kawase, Kazuhiro Nakatani, Kazumi Tsubakio-Yamamoto, Daisaku Masuda, Tohru Ohama, Akifumi Matsuyama, Masato Ishigami, Makoto Nishida, Issei KomuroShizuya Yamashita

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicron remnants synthesized in the small intestines. The serum concentration of apoB-48 at fasting has been reported to be a marker of postprandial hyperlipidemia, a presumed risk factor for atherosclerosis. Methods: We evaluated the basal performance of a recently developed chemiluminescent enzyme immunoassay (CLEIA). We also examined the correlations between serum apoB-48 concentrations and other lipid concentrations or life style patterns, including smoking and drinking. We analyzed the data of 273 clinical samples by multiple regression analysis to examine the influence of other serum lipid values, age, sex, smoking, drinking status and BMI on serum apoB-48 values. Results: Within-run and between-run precision was obtained with 1.7-2.7% and 1.2-7.3%, respectively. The correlativity of enzyme-linked immunosorbent assay was correlation coefficient r = 0.953, and regression y = 1.02 × -1.59. Serum apoB-48 concentrations were higher in males than in females, and were correlated with the status of smoking as well as with remnant-like particle-cholesterol (RLP-C) concentrations. Patients with the metabolic syndrome showed higher values of serum apoB-48 compared with control subjects. Conclusion: Serum apoB-48 measurement by CLEIA was satisfactory for clinical use to assess abnormalities in the chylomicron remnant metabolism.

Original languageEnglish
Pages (from-to)160-165
Number of pages6
JournalClinica Chimica Acta
Volume413
Issue number1-2
DOIs
Publication statusPublished - 18-01-2012

Fingerprint

Chylomicron Remnants
Apolipoprotein B-48
Chemiluminescence
Luminescence
Immunoenzyme Techniques
Metabolism
Enzymes
Serum
Smoking
Drinking
Luminescent Measurements
Lipids
Immunosorbents
Hyperlipidemias
Regression analysis
Small Intestine
Life Style
Assays
Fasting
Atherosclerosis

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hanada, Hiroyuki ; Mugii, Satomi ; Okubo, Manabu ; Maeda, Ikuhiro ; Kuwayama, Kazuya ; Hidaka, Yoh ; Kitazume-Taneike, Rika ; Yamashita, Taiji ; Kawase, Ryota ; Nakaoka, Hajime ; Inagaki, Miwako ; Yuasa-Kawase, Miyako ; Nakatani, Kazuhiro ; Tsubakio-Yamamoto, Kazumi ; Masuda, Daisaku ; Ohama, Tohru ; Matsuyama, Akifumi ; Ishigami, Masato ; Nishida, Makoto ; Komuro, Issei ; Yamashita, Shizuya. / Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. In: Clinica Chimica Acta. 2012 ; Vol. 413, No. 1-2. pp. 160-165.
@article{ec80fdff011c45f9987629bf0b362a0c,
title = "Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism",
abstract = "Background: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicron remnants synthesized in the small intestines. The serum concentration of apoB-48 at fasting has been reported to be a marker of postprandial hyperlipidemia, a presumed risk factor for atherosclerosis. Methods: We evaluated the basal performance of a recently developed chemiluminescent enzyme immunoassay (CLEIA). We also examined the correlations between serum apoB-48 concentrations and other lipid concentrations or life style patterns, including smoking and drinking. We analyzed the data of 273 clinical samples by multiple regression analysis to examine the influence of other serum lipid values, age, sex, smoking, drinking status and BMI on serum apoB-48 values. Results: Within-run and between-run precision was obtained with 1.7-2.7{\%} and 1.2-7.3{\%}, respectively. The correlativity of enzyme-linked immunosorbent assay was correlation coefficient r = 0.953, and regression y = 1.02 × -1.59. Serum apoB-48 concentrations were higher in males than in females, and were correlated with the status of smoking as well as with remnant-like particle-cholesterol (RLP-C) concentrations. Patients with the metabolic syndrome showed higher values of serum apoB-48 compared with control subjects. Conclusion: Serum apoB-48 measurement by CLEIA was satisfactory for clinical use to assess abnormalities in the chylomicron remnant metabolism.",
author = "Hiroyuki Hanada and Satomi Mugii and Manabu Okubo and Ikuhiro Maeda and Kazuya Kuwayama and Yoh Hidaka and Rika Kitazume-Taneike and Taiji Yamashita and Ryota Kawase and Hajime Nakaoka and Miwako Inagaki and Miyako Yuasa-Kawase and Kazuhiro Nakatani and Kazumi Tsubakio-Yamamoto and Daisaku Masuda and Tohru Ohama and Akifumi Matsuyama and Masato Ishigami and Makoto Nishida and Issei Komuro and Shizuya Yamashita",
year = "2012",
month = "1",
day = "18",
doi = "10.1016/j.cca.2011.09.013",
language = "English",
volume = "413",
pages = "160--165",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

Hanada, H, Mugii, S, Okubo, M, Maeda, I, Kuwayama, K, Hidaka, Y, Kitazume-Taneike, R, Yamashita, T, Kawase, R, Nakaoka, H, Inagaki, M, Yuasa-Kawase, M, Nakatani, K, Tsubakio-Yamamoto, K, Masuda, D, Ohama, T, Matsuyama, A, Ishigami, M, Nishida, M, Komuro, I & Yamashita, S 2012, 'Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism', Clinica Chimica Acta, vol. 413, no. 1-2, pp. 160-165. https://doi.org/10.1016/j.cca.2011.09.013

Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. / Hanada, Hiroyuki; Mugii, Satomi; Okubo, Manabu; Maeda, Ikuhiro; Kuwayama, Kazuya; Hidaka, Yoh; Kitazume-Taneike, Rika; Yamashita, Taiji; Kawase, Ryota; Nakaoka, Hajime; Inagaki, Miwako; Yuasa-Kawase, Miyako; Nakatani, Kazuhiro; Tsubakio-Yamamoto, Kazumi; Masuda, Daisaku; Ohama, Tohru; Matsuyama, Akifumi; Ishigami, Masato; Nishida, Makoto; Komuro, Issei; Yamashita, Shizuya.

In: Clinica Chimica Acta, Vol. 413, No. 1-2, 18.01.2012, p. 160-165.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism

AU - Hanada, Hiroyuki

AU - Mugii, Satomi

AU - Okubo, Manabu

AU - Maeda, Ikuhiro

AU - Kuwayama, Kazuya

AU - Hidaka, Yoh

AU - Kitazume-Taneike, Rika

AU - Yamashita, Taiji

AU - Kawase, Ryota

AU - Nakaoka, Hajime

AU - Inagaki, Miwako

AU - Yuasa-Kawase, Miyako

AU - Nakatani, Kazuhiro

AU - Tsubakio-Yamamoto, Kazumi

AU - Masuda, Daisaku

AU - Ohama, Tohru

AU - Matsuyama, Akifumi

AU - Ishigami, Masato

AU - Nishida, Makoto

AU - Komuro, Issei

AU - Yamashita, Shizuya

PY - 2012/1/18

Y1 - 2012/1/18

N2 - Background: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicron remnants synthesized in the small intestines. The serum concentration of apoB-48 at fasting has been reported to be a marker of postprandial hyperlipidemia, a presumed risk factor for atherosclerosis. Methods: We evaluated the basal performance of a recently developed chemiluminescent enzyme immunoassay (CLEIA). We also examined the correlations between serum apoB-48 concentrations and other lipid concentrations or life style patterns, including smoking and drinking. We analyzed the data of 273 clinical samples by multiple regression analysis to examine the influence of other serum lipid values, age, sex, smoking, drinking status and BMI on serum apoB-48 values. Results: Within-run and between-run precision was obtained with 1.7-2.7% and 1.2-7.3%, respectively. The correlativity of enzyme-linked immunosorbent assay was correlation coefficient r = 0.953, and regression y = 1.02 × -1.59. Serum apoB-48 concentrations were higher in males than in females, and were correlated with the status of smoking as well as with remnant-like particle-cholesterol (RLP-C) concentrations. Patients with the metabolic syndrome showed higher values of serum apoB-48 compared with control subjects. Conclusion: Serum apoB-48 measurement by CLEIA was satisfactory for clinical use to assess abnormalities in the chylomicron remnant metabolism.

AB - Background: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicron remnants synthesized in the small intestines. The serum concentration of apoB-48 at fasting has been reported to be a marker of postprandial hyperlipidemia, a presumed risk factor for atherosclerosis. Methods: We evaluated the basal performance of a recently developed chemiluminescent enzyme immunoassay (CLEIA). We also examined the correlations between serum apoB-48 concentrations and other lipid concentrations or life style patterns, including smoking and drinking. We analyzed the data of 273 clinical samples by multiple regression analysis to examine the influence of other serum lipid values, age, sex, smoking, drinking status and BMI on serum apoB-48 values. Results: Within-run and between-run precision was obtained with 1.7-2.7% and 1.2-7.3%, respectively. The correlativity of enzyme-linked immunosorbent assay was correlation coefficient r = 0.953, and regression y = 1.02 × -1.59. Serum apoB-48 concentrations were higher in males than in females, and were correlated with the status of smoking as well as with remnant-like particle-cholesterol (RLP-C) concentrations. Patients with the metabolic syndrome showed higher values of serum apoB-48 compared with control subjects. Conclusion: Serum apoB-48 measurement by CLEIA was satisfactory for clinical use to assess abnormalities in the chylomicron remnant metabolism.

UR - http://www.scopus.com/inward/record.url?scp=82955212918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955212918&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2011.09.013

DO - 10.1016/j.cca.2011.09.013

M3 - Article

C2 - 21958700

AN - SCOPUS:82955212918

VL - 413

SP - 160

EP - 165

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -